… , so most patients are focused on a targeted treatment and immune checkpoint inhibitors [5,7]. …
checkpoint inhibitors is also a hot spot in recent research. At present, the combination of …

… Lenvatinib is regarded as the first-line therapy for patients with unresectable hepatocellular
… and safety of lenvatinib with or without immune checkpoint inhibitors (ICIs) in patients with …

… patients with advanced hepatocellular carcinoma who were treated with lenvatinib plus immune
checkpoint inhibitors. … In this study, the combination of lenvatinib plus ICIs improved both …

… on PD−1/PD-L1 blockade is unknown. In this work, we evaluated the safety and efficacy of
lenvatinib administration after PD-1/PD-L1 checkpoint blockade. The outcome and safety of …

… lenvatinib plus anti-PD-1 inhibitors may achieve greater therapeutic benefits for uHCC patients.
… efficacy and safety of TACE combined with lenvatinib plus anti-PD-1 inhibitors for uHCC. …

… patients, the clinical benefit of combining ICI with lenvatinib … patient receiving lenvatinib
and whether the combining ICI with lenvatinib provides a greater survival benefit than lenvatinib …

… Lenvatinib (LEN) is a multikinase VEGFR inhibitor approved for use in combination with …
specifically in patients (pts) who progressed with prior immune checkpoint inhibitor (ICI) therapy. …

… of lenvatinib plus everolimus for patients with ccRCC or nccRCC [28]. Our cohort included
42 patients who received lenvatinib plus everolimus and 13 patients who received lenvatinib …

500 Background: Lenvatinib (Len) is a multikinase inhibitor targeting VEGFR 1-3, FGFR 1-4
and other kinases. Pembrolizumab (Pem) and nivolumab (Nivo) are antibodies inhibiting …

… lenvatinib and PD-1 inhibitor at the same time, or patients who received PD-1 inhibitor within
1 week of lenvatinib … (TP), patients treated with PD-1 inhibitors after more than 3 months of …